Lumosa Therapeutics Co., Ltd.

Lumosa Therapeutics (TPEX: 6535), founded in 2000 in Taipei, Taiwan, is a clinical-stage biopharmaceutical company focused on neurological and oncological diseases with urgent unmet medical needs. Its lead candidate LT3001 (Odatroltide), a first-in-class dual-function therapy combining safe reperfusion and direct neuroprotection for acute ischemic stroke, received FDA Fast Track Designation.